COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Their focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. Currently, COMPASS is pioneering the development of a new model of psilocybin therapy, in which their proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.
COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD). COMPASS is headquartered in London, UK, with offices in New York, USA.
Stock Performance
COMPASS Pathways News 113 articles
- Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
- Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
- Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360
- Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
- Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
- Compass Pathways to Participate in Investor Conferences the Week of September 14th
- Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
- Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026
- Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree
- Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026
- Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
- Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
- Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
- Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026
- Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy
- 2026 Mid-Year Psychedelic Industry Report
- Compass Pathways reports six-month Phase 3 COMP006 data confirming durable psilocybin response
- Compass reports Q1 2026 results with $466 million cash position
- Compass sets May 13 date for first-quarter 2026 results
- FDA grants Compass rolling NDA review and a National Priority Voucher for COMP360
- Compass commends White House psychedelics executive order
- Compass opens U.S. grant program to build COMP360 provider training
- 2026 Q1 Psychedelic Industry Report
- Compass reports 2025 results, says cash runway extends into 2028
- Compass prices $150 million public offering on the heels of Phase 3 data
- Compass hits primary endpoint in second Phase 3 psilocybin trial, giving it two positive pivotal studies
- Trump administration officials strip Compass psilocybin from FDA fast-track voucher list
- FDA accepts Compass Pathways' IND for COMP360 psilocybin in PTSD
- Compass accelerates commercial launch plans by 9-12 months in Q3 update
- 2025 Q3 Psychedelic Industry Report
- Compass publishes Phase 2 results for COMP360 psilocybin in PTSD
- Compass Pathways posts Q2 2025 results and weighs an accelerated COMP360 filing
- Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
- Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
- Compass Pathways Streamlines Operations with Workforce Reduction and Shift in Research Focus
- Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
- Is Compass Pathways Poised for Success?
- Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
Showing the 40 most recent of 113 articles.